ArticleScientific reports2018
Suppression of Staphylococcus aureus biofilm formation and virulence by a benzimidazole derivative, UM-C162.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 134 citations in OpenAlex.
- Stage V sporulation protein G as a global regulator of biofilm formation and virulence in Staphylococcus species: molecular mechanisms and therapeutic potential.World journal of microbiology & biotechnology · 2026Review
- Integrated In Vitro and In Silico Evaluation of Benzimidazolium Salts: Antioxidant Activity, Anti-MRSA/MSSA Effects, and Antibacterial Gene Expression Analysis.Antibiotics (Basel, Switzerland) · 2026Article
- Advancements in antiviral activity of aza-heterocyclic compounds: a review.Molecular diversity · 2026Review
- Antibacterial and Antibiofilm Potential of Thymol-Benzimidazolium-Chalcone Hybrids Against Clinical MRSA Strains: Insights from Gene Expression Profiling and Molecular Docking.Antibiotics (Basel, Switzerland) · 2026Article
- Daphnoretin as a potent sortase A inhibitor effectively disarms drug-resistant Staphylococcus aureus infections.World journal of microbiology & biotechnology · 2026Article
- Effect ofPathogens (Basel, Switzerland) · 2026Article
- Z‑Amino Acids Present Innovative Antimicrobial and Antibiofilm Properties against Methicillin-Susceptible and -ResistantACS omega · 2026Article
- Indolenine-substituted pyrazole derivative 4e inhibits planktonicAntimicrobial agents and chemotherapy · 2025Article
- Tripterhyponoid A fromMolecules (Basel, Switzerland) · 2025Article
- Enhanced Biofilm Disruption in Methicillin-ResistantPathogens (Basel, Switzerland) · 2025Article
- In vivo virulence ofJTCVS open · 2025Article
- The Therapeutic Efficacy of MS473, a Fully Human Single-Chain Variable Fragment Targeting Staphylococcus aureus Toxic Shock Syndrome Toxin-1, in a D-Galactosamine-Sensitized Mouse Model of Lethal Shock.BMC microbiology · 2025Article
- Biofilm destruction activity of α-tocopherol against Staphylococcus aureus, Proteus mirabilis, and Pseudomonas aeruginosa.FEMS microbiology letters · 2025Article
- Potential antivirulence and antibiofilm activities of sub-MIC of oxacillin against MDR S. aureus isolates: an in-vitro and in-vivo study.BMC microbiology · 2024Article
- Antimycobacterial and Anticancer Properties ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Unveiling antibiofilm potential: proteins from Priestia sp. targeting Staphylococcus aureus biofilm formation.Antonie van Leeuwenhoek · 2024Article
- Medical Device-Associated Biofilm Infections and Multidrug-Resistant Pathogens.Pathogens (Basel, Switzerland) · 2024Review
- Effectiveness of cephalosporins in hydrolysis and inhibition ofJournal of veterinary science · 2024Article
- Oxidative Stress-Mediated Repression of Virulence Gene Transcription and Biofilm Formation as Antibacterial Action ofInternational journal of molecular sciences · 2024Article
- Bactericidal and biofilm eradication efficacy of a fluorinated benzimidazole derivative, TFBZ, against methicillin-resistantFrontiers in pharmacology · 2024Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus is a major cause of nosocomial infections and secretes a diverse spectrum of virulence determinants as well as forms biofilm. The emergence of antibiotic-resistant S. aureus highlights the need for alternative forms of therapeutics other than conventional antibiotics. One route to meet this need is screening small molecule derivatives for potential anti-infective activity. Using a previously optimized C. elegans - S. aureus small molecule screen, we identified a benzimidazole derivative, UM-C162, which rescued nematodes from a S. aureus infection. UM-C162 prevented the formation of biofilm in a dose-dependent manner without interfering with bacterial viability. To examine the effect of UM-C162 on the expression of S. aureus virulence genes, a genome-wide transcriptome analysis was performed on UM-C162-treated pathogen. Our data indicated that the genes associated with biofilm formation, particularly those involved in bacterial attachment, were suppressed in UM-C162-treated bacteria. Additionally, a set of genes encoding vital S. aureus virulence factors were also down-regulated in the presence of UM-C162. Further biochemical analysis validated that UM-C162-mediated disruption of S. aureus hemolysins, proteases and clumping factors production. Collectively, our findings propose that UM-C162 is a promising compound that can be further developed as an anti-virulence agent to control S. aureus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.